Site search- 2026.9.8PRBrightPath to Present Preclinical Data of iPSC-Derived BCMA CAR-iNKT Cell Therapy (BP2202) at IMS 2026（106KB）
- 2026.8.14IRFinancial Results for the Three Months ended June 30, 2026〔Japanese GAAP〕(non-consolidated)（399KB）
- 2026.8.3IRFDA Clearance of Investigational New Drug Application for BP2202（115KB）
- 2026.7.2IRBrightPath Submits IND Application to U.S. FDA for the First-in-human Phase 1 Trial of BP2202（144KB）
- 2026.5.14IRFinancial Results for the Fiscal Year ended March 31, 2026 [Japanese GAAP] (non-consolidated)（455 KB）
- 2026.2.13IRFinancial Results for the Nine Months ended December 31, 2025 [Japanese GAAP] (non-consolidated)（297 KB）
- 2026.8.14IRFinancial Results for the Three Months ended June 30, 2026〔Japanese GAAP〕(non-consolidated)（399KB）
- 2026.8.3IRFDA Clearance of Investigational New Drug Application for BP2202（115KB）
- 2026.7.2IRBrightPath Submits IND Application to U.S. FDA for the First-in-human Phase 1 Trial of BP2202（144KB）
- 2026.5.14IRFinancial Results for the Fiscal Year ended March 31, 2026 [Japanese GAAP] (non-consolidated)（455 KB）
- 2026.2.13IRFinancial Results for the Nine Months ended December 31, 2025 [Japanese GAAP] (non-consolidated)（297 KB）